Q-ABSORBANCE RATIO SPECTROPHOTOMETRIC METHOD FOR THE SIMULTANEOUS ESTIMATION OF VARDENAFIL AND DAPOXETINE HYDROCHLORIDE IN THEIR COMBINED DOSAGE FORM

Bipin Paghadar*1, Hiren Antala1, Pratik Tala1, Komal Dhudashia1, Neelam Patel2
*1Department of Quality Assurance, Noble Pharmacy College, Junagadh, Gujarat, India.
2Department of Quality Assurance, B. M. Shah Pharmacy College, Modasa, Gujarat, India.

ABSTRACT
The present manuscript describes simple, sensitive, rapid, accurate, precise and economical Q-absorbance ratio method for the simultaneous determination of Vardenafil and Dapoxetine HCl in combined dosage form. Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an is absorptive point and other being the $\lambda$-max of one of the two components. Vardenafil and Dapoxetine HCl show an is absorptive point at 270 nm in water. The second wavelength used is 292 nm, which is the $\lambda$-max of Dapoxetine HCl in water. The linearity was obtained in the concentration range of 1-5 $\mu$g/ml for Vardenafil and 10-30 $\mu$g/ml for Dapoxetine HCl. The concentrations of the drugs were determined by using ratio of absorbances at is absorptive point and at the $\lambda$-max of Dapoxetine HCl. The method was successfully applied to pharmaceutical dosage form because no interference. The results of analysis have been validated statistically and by recovery studies.

KEY WORDS
Dapoxetine HCl, Vardenafil, Absorbance ratio method, Is absorptive point and Validation.

Author for Correspondence:
Bipin Paghadar,
Noble College of Pharmacy, Jungadh,
Gujarat, India.

Email: paghadarbipin@gmail.com

INTRODUCTION
Vardenafil$^1$ (VAR) is chemically 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propyl-midazo [5,1f]
[1,2,4] triazin-2-yl)-4-ethoxyphenyl]sulfonyl] -4-ethylpipera-zine. Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP). Vardenafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH) (Figure No.1).
Dapoxetine hydrochloride\(^2\) (DAP Hcl) is chemically \((S)-N,N\) dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine. Dapoxetine hydrochloride is indicated for the treatment of premature ejaculation and erectile dysfunction in men aged 18-64 years (Figure No.2).

The combined dosage forms of VAR and DAP Hcl are available in the market for the treatment of erectile dysfunction and premature ejaculation. The combination of these two drugs is not official in any pharmacopoeia; hence no official method is available for the simultaneous estimation of VAR and DAP Hcl in their combined dosage forms. Literature survey does not reveal any spectrophotometric method for simultaneous estimation of VAR and DAP Hcl in combined dosage forms. The present communication describes simple, specific, rapid, accurate and precise chromatographic method based on Q-absorption spectrophotometric method\(^3\) for simultaneous estimation of both drugs in their combined tablet dosage forms.

**MATERIAL AND METHODS**

**Instrument**
A Shimadzu UV-1800 double beam UV/Visible spectrophotometer with spectral width of 2 nm, wavelength accuracy of 0.5 nm and a pair of 10 mm matched quartz cell was used to measure absorbance of all the solutions. Spectra were automatically obtained by UV-Probe system software. A Scale- tec\(^{TM}\) analytical balance and ultrasonic bath was used in the study.

**Reagents and Materials**
VAR bulk powder was kindly purchased by Centurioan Laboratories Private Limited, Baroda, Gujarat, India and DAP Hcl bulk powder kindly supplied as a gift sample by Ami Life science pvt. Ltd. Akota, Baroda, Gujarat, India. The commercial fixed dose combination product Super Vilitra was kindly purchased by Centurioan Laboratories, Baroda, India. Were used in study.

**Preparation of Standard Solutions**
A 10 mg of standard VAR and DAP Hcl were weighed and transferred to 100 ml separate volumetric flasks and dissolved in distil water. The flasks were shaken and volumes were made up to mark with distil water to give a solution containing 100\(\mu\)g/ml each of VAR and DAP Hcl.

**Methodology**
Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an isoabsorptive point and other being the \(\lambda\)-max of one of the two components. From the overlay spectra of two drugs, it is evident that VAR and DAP Hcl show an isoabsorptive point at 270 nm. The second wavelength used is 292 nm, which is the \(\lambda\)-max of DAP Hcl. Working standard solutions having concentration 1, 2, 3, 4, and 5 \(\mu\)g/ml for VAR and 10, 15, 20, 25, and 30 \(\mu\)g/ml for DAP Hcl were prepared in distil water and the absorbances at 270 nm (isoabsorptive point) and 292 nm (\(\lambda\)-max of DAP Hcl) were measured and absorptivity coefficients were calculated using calibration curve.

The concentration of two drugs in the mixture can be calculated using following equations.

\[
CX = \left[\frac{(QM - QY)}{(QX - QY)}\right] \times \frac{A_1}{a_1} \quad \text{(1)}
\]

\[
CY = \left[\frac{(QM - QX)}{(QY - QX)}\right] \times \frac{A_1}{a_1} \quad \text{(2)}
\]

Where, \(A_1\) and \(A_2\) are absorbances of mixture at 270 nm and 292 nm; \(a_1\) and \(a_2\) are absorptivities of VAR and DAP Hcl respectively.

**Validation of the proposed method**
The proposed method was validated according to the International Conference on Harmonization (ICH) guideline.

**Linearity (calibration curve)**
The calibration curves were plotted over a concentration range of 1-5 \(\mu\)g/ml for VAR and 10-30 \(\mu\)g/ml for DAP Hcl. Appropriate aliquots from the standard stock solutions of VAR and DAP Hcl were used to prepare two different sets of dilutions: Series A, and B as follows. Series A consisted of different concentration of VAR (1-5 \(\mu\)g/ml). Aliquot from the stock solution of VAR (100 \(\mu\)g/ml) was pipette out in to a series of 10 ml volumetric flask and diluted with distilled water to
get final concentration in range of 1-5 μg/ml (0.1, 0.2, 0.3, 0.4, and 0.5 ml). Series B consisted of varying concentrations of DAP Hcl (10-30 μg/ml).

Appropriate volume of the stock solution of DAP Hcl (100 μg/ml) was transferred into a series of 10 ml volumetric flask and the volume was adjusted to the mark with distill water to get final concentration in range of 10-30 μg/ml (1, 1.5, 2.0, 2.5, and 3.0 ml). The absorbances of solution were then measured at 270 nm and 292 nm. The calibration curves were constructed by plotting absorbances versus concentration and the regression equations were calculated (Figure No.3).

Method precision (repeatability)
The precision of the instrument was checked by repeated scanning and measurement of absorbance of solutions (n = 6) for VAR and DAP Hcl 3 μg/ml and 15 μg/ml respectively without changing the parameter of the proposed Spectrophotometry method.

Intermediate precision (reproducibility)
The intraday and interday precision of the proposed method was determined by analyzing the corresponding responses 3 times on the same day and on 3 different days over a period of 1 week for 3 different concentrations of standard solutions of VAR (2, 3, and 4 μg/ml) and for DAP Hcl (15, 20 and 25 μg/ml). The result was reported in terms of relative standard deviation (% RSD).

Accuracy (recovery study)
The accuracy of the method was determined by calculating the recoveries of VAR and DAP Hcl by the standard addition method. Known amounts of standard solutions of VAR and DAP Hcl were at added at 80, 100 and 120 % level to prequantified sample solutions of VAR and DAP Hcl (6μg/ml for VAR and 15μg/ml for DAP Hcl). The amounts of VAR and DAP Hcl were estimated by applying obtained values to the respective regression line equations.

Limit of detection and limit of quantification
The limit of detection (LOD) and the limit of quantification (LOQ) of the drug were derived by Calculating the signal-to-noise ratio (S/N, i.e., 3.3 for LOD and 10 for LOQ) using the following equations designated by International Conference on Harmonization (ICH) guidelines.

\[
\text{LOD} = 3.3 \times \frac{\sigma}{S} \quad \text{…….. (3)}
\]

\[
\text{LOQ} = 10 \times \frac{\sigma}{S} \quad \text{………. (4)}
\]

Where, \(\sigma\) = the standard deviation of the response and \(S\) = slope of the calibration curve.

Analysis of drugs in sample
The absorbances of the sample solution i.e. A1 and A2 were recorded at 270 nm and 292 nm (λ-max of DAP) respectively, and ratios of absorbance were calculated, i.e. A2/A1. Relative concentration of two drugs in the sample was calculated using above equation (1) and (2). The analysis procedure was repeated six times with tablet mixture.

RESULTS AND DISCUSSION
In absorbance ratio method (Q-analysis), the primary requirement for developing a method for analysis is that the entire spectra should follow the Beer’s law at all the wavelength, which was fulfilled in case of both these drugs. The two wavelengths were used for the analysis of the drugs were 270 nm (isoabsorptive point) and 292 nm (λ-max of DAP Hcl) at which the calibration curves were prepared for both the drugs. The overlain UV absorption spectra of VAR (214 nm) and DAP (292 nm) showing isoabsorptive point (270 nm) in distill water is shown in Figure No.4. The validation parameters were studied at all the wavelengths for the proposed method. Accuracy was determined by calculating the recovery and the mean was determined (Table No.2). The method was successfully used to determine the amounts of VAR and DAP Hcl present in the tablet mixture. The results obtained were in good agreement with the corresponding labeled amount (Table No.3). Precision was calculated as repeatability and intra and inter day variations (% RSD) for both the drugs. Optical characteristics and summary of validation parameters for method is given in Table No.1. By observing the validation parameters, the method was found to be simple, sensitive, accurate and precise. Hence the method can be employed for the routine analysis of these two drugs in combined dosage form.
Table No.1: Regression analysis data and Summary of validation parameters for VAR and DAP Hcl by Q-Absorbance Spectrophotometric method

<table>
<thead>
<tr>
<th>S.No</th>
<th>Parameters</th>
<th>Isoabsorptive point of VAR and DAP Hcl at 270 nm</th>
<th>λ-max of DAP Hcl at 292 nm</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Concentration range (µg/mL)</td>
<td>1-5</td>
<td>10-30</td>
</tr>
<tr>
<td>2</td>
<td>Slope</td>
<td>0.038</td>
<td>0.021</td>
</tr>
<tr>
<td>3</td>
<td>Intercept</td>
<td>0.015</td>
<td>0.007</td>
</tr>
<tr>
<td>4</td>
<td>Correlation coefficient</td>
<td>0.997</td>
<td>0.999</td>
</tr>
<tr>
<td>5</td>
<td>Accuracy ± SDa</td>
<td>99.78 ± 0.64 - 100.32 ± 0.32</td>
<td>99.78 ± 0.24 – 100.87 ± 0.18</td>
</tr>
<tr>
<td>6</td>
<td>LODb (µg/mL)</td>
<td>0.1193</td>
<td>0.314</td>
</tr>
<tr>
<td>7</td>
<td>LOQc (µg/mL)</td>
<td>0.363</td>
<td>0.952</td>
</tr>
<tr>
<td>8</td>
<td>Repeatability (% RSDd, n = 6)</td>
<td>1.07</td>
<td>0.451</td>
</tr>
<tr>
<td>9</td>
<td>Precision (% RSD)</td>
<td>Interday (n = 3)</td>
<td>0.97-1.4</td>
</tr>
<tr>
<td></td>
<td>Intraday (n = 3)</td>
<td>0.97-1.53</td>
<td>0.28-0.73</td>
</tr>
</tbody>
</table>

aSD= Standard deviation, bLOD = Limit of detection, cLOQ = Limit of quantification, dRSD = Relative standard deviation.

Table No.2: Recovery data of VAR and DAP Hcl by Spectrophotometric method

<table>
<thead>
<tr>
<th>S.No</th>
<th>Drug</th>
<th>Level</th>
<th>Amount of sample taken (µg/mL)</th>
<th>Amount of standard spiked (%)</th>
<th>% Recovery ± SD (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>VAR</td>
<td>I</td>
<td>6</td>
<td>80 %</td>
<td>100.32 ± 0.32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>6</td>
<td>100 %</td>
<td>100 ± 0.48</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>6</td>
<td>120 %</td>
<td>99.78 ± 0.64</td>
</tr>
<tr>
<td>2</td>
<td>DAP Hcl</td>
<td>I</td>
<td>15</td>
<td>80 %</td>
<td>100.87 ± 0.18</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>15</td>
<td>100 %</td>
<td>99.75 ± 0.24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>15</td>
<td>120 %</td>
<td>100.37 ± 0.06</td>
</tr>
</tbody>
</table>

Table No.3: Analysis of VAR and DAP Hcl by Spectrophotometric Method

<table>
<thead>
<tr>
<th>S.No</th>
<th>Mixture</th>
<th>Label claim</th>
<th>Amount found</th>
<th>% Label claim (%RSD, n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>VAR 20 + DAP 60</td>
<td>VAR/TAB</td>
<td>20.08 mg</td>
<td>100.46 ± 0.86 %</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DAP.Hcl/TAB</td>
<td>59.84 mg</td>
<td>99.73 ± 2.09 %</td>
</tr>
</tbody>
</table>

Available online: www.uptodateresearchpublication.com  January - February 127
Figure No.1: Structure of Vardenafil

Figure No.2: Structure of Dapoxetine Hydrochloride

Figure No.3: Linearity of VAR and DAP Hcl in Distilled water

Figure No.4: Overlain absorption spectra of Vardenafil (214 nm) and Dapoxetine HCL (292 nm) showing isoabsorptive point (270 nm) in distil water
CONCLUSION
The proposed spectrophotometric method was found to be simple, sensitive, accurate and precise for determination of VAR and DAP HCl in Tablet mixture. The method utilizes easily available and cheap solvent for analysis of VAR and DAP HCl hence the method was also economic for estimation of VAR and DAP HCl from Tablet mixture. The common excipients and other additives are usually present in the Tablet mixture do not interfere in the analysis of VAR and DAP HCl in distil water, hence it can be conveniently adopted for routine quality control analysis of the drugs in combined pharmaceutical formulation.

ACKNOWLEDGEMENT
The authors are thankful to Ami Life science pvt. ltd, Baroda, Gujarat, India for providing gift sample DAP HCl for research. The authors are highly thankful to Noble College of Pharmacy, Junagadh, Gujarat, India for providing all the facilities to carry out the work.

CONFLICT OF INTEREST
We declare that we have no conflict of interest.

REFERENCES

Please cite this article in press as: Bipin Paghadar. et al. Q-absorbance ratio spectrophotometric method for the simultaneous estimation of vardenafil and dapoxetine hydrochloride in their combined dosage form, International Journal of Research in Pharmaceutical and Nano Sciences, 2(1), 2013, 124-129.